Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 7/20 | 0.35 |
| ▸ | KLK1 | P06870 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16132838 | 0.86 | NOTUM (0.50) | NOTUMALDH1A1F2NPSR1F11 | |
| SCHEMBL20354113 | 0.79 | CYP2C9 (0.36) | ALDH1A1KMT2A | |
| SCHEMBL14873801 | 0.78 | NOTUM (0.50) | NOTUMALDH1A1F2NPSR1F11 | |
| SCHEMBL14873776 | 0.76 | NOTUM (0.54) | NOTUMALDH1A1F2HTTNPSR1 | |
| SCHEMBL23088219 | 0.73 | NOTUM (0.51) | NOTUMALDH1A1F2NPSR1F11 | |
| SCHEMBL23088294 | 0.73 | NOTUM (0.51) | NOTUMALDH1A1F2NPSR1F11 | |
| SCHEMBL29792599 | 0.73 | NOTUM (0.51) | NOTUMALDH1A1F2NPSR1F11 | |
| SCHEMBL24427290 | 0.73 | NOTUM (0.54) | NOTUMALDH1A1F2NPSR1F11 | |
| SCHEMBL23486492 | 0.73 | NOTUM (0.54) | NOTUMALDH1A1F2NPSR1F11 | |
| SCHEMBL10257379 | 0.73 | NOTUM (0.45) | NOTUMF11KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336754-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336754-B2 | Pyrimidinones as factor XIa inhibitors | TFPI, TFPI2, F2 | NOTUM 3214/4885ALDH1A1 2800/4885F2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.